Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim

Last Updated: October 18, 2019

DrugPatentWatch Database Preview

Drugs in Development Information for Perifosine

See Plans and Pricing

« Back to Dashboard

Drug Development Status for Perifosine: Sponsors, patents, clinical trial progress

Perifosine is an investigational drug.

There have been 43 clinical trials for Perifosine. The most recent clinical trial was a Phase 3 trial, which was initiated on December 1st 2009.

The most common disease conditions in clinical trials are Multiple Myeloma, Neoplasms, Plasma Cell, and Leukemia. The leading clinical trial sponsors are AEterna Zentaris, National Cancer Institute (NCI), and Dana-Farber Cancer Institute.

There are eight hundred and fifty-eight US patents protecting this investigational drug and eight international patents.

Recent Clinical Trials for Perifosine
Perifosine and Torisel (Temsirolimus) for Recurrent/Progressive Malignant GliomasAEterna ZentarisPhase 2
Perifosine and Torisel (Temsirolimus) for Recurrent/Progressive Malignant GliomasPfizerPhase 2
Perifosine and Torisel (Temsirolimus) for Recurrent/Progressive Malignant GliomasAndrew LassmanPhase 2

See all Perifosine clinical trials

Clinical Trial Summary for Perifosine

Top disease conditions for Perifosine
Top clinical trial sponsors for Perifosine

See all Perifosine clinical trials

US Patents for Perifosine

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Perifosine   Start Trial Compounds and their methods of use Agios Pharmaceuticals, Inc. (Cambridge, MA)   Start Trial
Perifosine   Start Trial Peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers IMMATICS BIOTECHNOLOGIES GMBH (Tuebingen, DE)   Start Trial
Perifosine   Start Trial Therapeutic uses of selected pyrrolopyrimidine compounds with anti-mer tyrosine kinase activity The University of North Carolina at Chapel Hill (Chapel Hill, NC)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.